<html><head>
<meta http-equiv="content-type" content="text/html; charset=UTF-8"><script>
function toggleSelectedText(e) {
    if (e.shiftKey) {
        var selection = window.getSelection();
        var range = selection.getRangeAt(0);
        var tags = "p,h1,h2,h3,h4,h5,h6,ul,ol,li,dl,dt,table,tr,td,th,article,main,section,figure,figcaption,aside,section,address,blockquote,code";
        if (range.commonAncestorContainer.getElementsByTagName) {
            var allWithinRangeParent = range.commonAncestorContainer.querySelectorAll(tags);
        }
        else {
            //var allWithinRangeParent = [range.commonAncestorContainer.closest(tags)];
            var allWithinRangeParent = [range.commonAncestorContainer.parentNode.closest(tags)];
        }

        for (var i=0, el; el = allWithinRangeParent[i]; i++) {
          // The second parameter says to include the element
          // even if it's not fully selected
          if (selection.containsNode(el, true) ) {
              el.classList.toggle('rm-manual');
          }
        }
        window.getSelection().removeAllRanges();
    }
};

//var article = document.body.querySelector('article');
document.onmouseup = toggleSelectedText;
document.captureEvents(Event.MOUSEUP);
</script>

<style>
.rm-manual {
    text-decoration: line-through;
    background-color: #faa;
}
</style>
        </head><body><article><p class="rm-manual"> Risque de variole, 
vaccination et bioterrorisme - ScienceDirect JavaScript is disabled on 
your browser. Please enable JavaScript to use all the features on this 
page. </p>
<p class="rm-manual"><a href="#screen-reader-main-content">Skip to main content</a> </p>
<p class="rm-manual"><a href="#screen-reader-main-title">Skip to article</a> </p>
<p class="rm-manual"><a href="file:///">ScienceDirect</a></p>
<ul class="rm-manual"><li class="rm-manual"><a href="file:///browse/journals-and-books"><span>Journals &amp; Books</span></a></li></ul>
<p class="rm-manual"><a href="file:///user/register?targetURL=%2Fscience%2Farticle%2Fpii%2FS0755498205838990"><span>Register</span></a><a href="file:///user/login?targetURL=%2Fscience%2Farticle%2Fpii%2FS0755498205838990"><span>Sign in</span></a></p>
<p class="rm-manual"><a href="file:///user/login?targetURL=%2Fscience%2Farticle%2Fpii%2FS0755498205838990"><span>Sign in</span></a><a href="file:///user/register?targetURL=%2Fscience%2Farticle%2Fpii%2FS0755498205838990"><span>Register</span></a></p>
<ul class="rm-manual"><li class="rm-manual"><a href="file:///browse/journals-and-books"><span>Journals &amp; Books</span></a></li></ul>
<ul class="rm-manual"><li class="rm-manual"><a href="https://service.elsevier.com/app/home/supporthub/sciencedirect/" rel="noopener noreferrer"><span>Help</span></a></li></ul>
<p class="rm-manual"><a href="file:///search">Advanced</a></p>
<h2 class="rm-manual"><a href="file:///science/journal/07554982">La Presse Médicale</a></h2>
<p class="rm-manual"><a href="file:///science/journal/07554982/34/2/part/P2">Volume 34, Issue 2, Part 2</a>, January 2005, Pages 177-184</p>
<p class="rm-manual"><span>Bioterrorisme</span></p>
<p class="rm-manual"><span>Risque de variole, vaccination et bioterrorisme</span></p>
<p class="rm-manual"><span>Risk of smallpox, vaccin, biowarfare</span></p>
<p class="rm-manual"><span>Author links open overlay panel</span><a href="#!"><span><span>P.</span><span>Bossi</span></span></a><a href="#!"><span><span>D.</span><span>Garin</span></span></a><a href="#!"><span><span>B.</span><span>Combadière</span></span></a><a href="#!"><span><span>É.</span><span>Rouleau</span></span></a><a href="#!"><span><span>S.</span><span>Rigaudeau</span></span></a><a href="#!"><span><span>B.</span><span>Lebrun-Vignes</span></span></a><a href="#!"><span><span>V.</span><span>Martinez</span></span></a><a href="#!"><span><span>B.</span><span>Autran</span></span></a><a href="#!"><span><span>F.</span><span>Bricaire</span></span></a></p>
<p class="rm-manual"><a href="https://doi.org/10.1016/S0755-4982(05)83899-0" rel="noreferrer noopener">https://doi.org/10.1016/S0755-4982(05)83899-0</a><a rel="noreferrer noopener" href="https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&amp;contentID=S0755498205838990&amp;orderBeanReset=true">Get rights and content</a></p>
<h2 class="rm-manual">Points essentiels</h2>
<dl>
<dt>•</dt>
<dd><p class="rm-manual">L’utilisation du virus de la variole comme arme
 biologique est ancienne. Face à la menace bioterriste avérée actuelle, 
des plans de lutte ont été rédigés ; l’un de leurs principaux objectifs 
repose sur la vaccination d’équipes dédiées à la prise en charge de 
sujets infectés et sur le stockage de doses de vaccins suffisantes pour 
toute la population d’un pays.</p></dd>
<dt class="rm-manual">•</dt>
<dd><p class="rm-manual">À la suite de l’éradication mondiale de la 
variole, la vaccination préventive a été arrêtée en France en 1978 pour 
la primo-vaccination, en 1984 pour les injections de rappel.</p></dd>
<dt class="rm-manual">•</dt>
<dd><p class="rm-manual">Les différentes souches vaccinales utilisées 
dans les vaccins de première génération sont des vaccins vivants 
atténués provenant du virus de la vaccine dont l’hôte naturel et 
l’origine demeurent inconnus. Les vaccins de seconde et troisième 
génération sont en cours d’étude; l’objectif principal est l’efficacité 
avec un minimum d’effets secondaires.</p></dd>
<dt class="rm-manual">•</dt>
<dd><p class="rm-manual">Les effets indésirables, connus essentiellement
 pour les vaccins de première génération, sont de 2 ordres: les uns, 
extrêmement rares, peuvent engager le pronostic vital; les autres, plus 
fréquents (10 à 15 % des patients) sont bénins.</p></dd>
<dt class="rm-manual">•</dt>
<dd><p class="rm-manual">En situation d’urgence, en présence de cas de 
variole, il ne devrait pas y avoir de contre-indications absolues à la 
vaccination.</p></dd>
<dt class="rm-manual">•</dt>
<dd><p class="rm-manual">Dans un contexte de bioterrorisme, il ne s’agit
 pas de réaliser une campagne de vaccination de masse de la population 
(avec ses risques non négligeables de décès et d’effets indésirables 
graves) en l’absence de toute menace avérée. En France, 5 niveaux 
d’alerte ont été définis, avec, dans chaque cas, une stratégie vaccinale
 à adopter.</p></dd>
</dl>
<h2>Key points</h2>
<dl>
<dt>•</dt>
<dd><p>The use of the smallpox virus as a biological weapon is very old.
 Confronted with a high probability of a currennt bioterrorist menace, 
counteracting strategies have been developed. One of the principle aims 
relies on the vaccination of teams dedicated to the management of 
persons infected and the stocking of sufficient doses of vaccine for the
 whole population of a country.</p></dd>
<dt>•</dt>
<dd><p>Following worldwide eradication of the disease, preventive 
vaccination was stopped in 1978 in France for the primo-vaccination, and
 in 1984 for repeat vaccinations.</p></dd>
<dt>•</dt>
<dd><p>The various strains used in the first generation vaccinations are
 weakened living vaccines from the virus of the vaccine, the natural 
host and origin of which are unknown. Second and third generations 
vaccines are under study; the principle objective is to obtain efficacy 
with a minimum of side effects.</p></dd>
<dt>•</dt>
<dd><p>There are two types of adverse events, generally observed with 
the first generation vaccines: the first, extremely rare, can be 
life-threatening; the others, more frequent (10 to 15% of patients) are 
benign.</p></dd>
<dt>•</dt>
<dd><p>In emergency situations in the presence of smallpox, there should be no absolute contraindications to vaccination.</p></dd>
<dt>•</dt>
<dd><p>In the bioterrorist context, massive vaccination campaigns of the
 population are unadvisable (because of the considerable risk of death 
and severe adverse events) in the absence of any real risk. In France, 5
 levels of alert have been established that permit, in each case, 
definition of the vaccinal strategy to be adopted.</p></dd>
</dl>
<p class="rm-manual"><a href="file:///science/article/pii/S0755498205838990"><span>View full text</span></a></p>
<p class="rm-manual"><span>Copyright © 2005 Elsevier Masson SAS. All rights reserved.</span></p>
<p class="rm-manual"><span>No articles found.</span></p>
<h2 class="rm-manual">Citing articles</h2>
<p class="rm-manual"><a href="https://plu.mx/plum/a/?doi=10.1016/S0755-4982(05)83899-0">View article metrics</a></p>
<ul>
<li class="rm-manual"><a href="https://www.elsevier.com/solutions/sciencedirect" rel="nofollow"><span>About ScienceDirect</span></a></li>
<li class="rm-manual"><a href="file:///customer/authenticate/manra" rel="nofollow"><span>Remote access</span></a></li>
<li class="rm-manual"><a href="https://sd-cart.elsevier.com/?" rel="nofollow"><span>Shopping cart</span></a></li>
<li class="rm-manual"><a href="http://elsmediakits.com/" rel="nofollow"><span>Advertise</span></a></li>
<li class="rm-manual"><a href="https://service.elsevier.com/app/contact/supporthub/sciencedirect/" rel="nofollow"><span>Contact and support</span></a></li>
<li class="rm-manual"><a href="https://www.elsevier.com/legal/elsevier-website-terms-and-conditions" rel="nofollow"><span>Terms and conditions</span></a></li>
<li class="rm-manual"><a href="https://www.elsevier.com/legal/privacy-policy" rel="nofollow"><span>Privacy policy</span></a></li>
</ul>
<p class="rm-manual">We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the <a href="https://www.sciencedirect.com/legal/use-of-cookies" rel="nofollow"><span>use of cookies</span></a>.</p>
<p class="rm-manual">Copyright © 2020 Elsevier B.V. or its licensors or contributors. <span>ScienceDirect ® is a registered trademark of Elsevier B.V.</span></p>
<p class="rm-manual">ScienceDirect ® is a registered trademark of Elsevier B.V.</p></article>
</body></html>